Gut microbiome-specific nanoparticle-based therapeutics for liver diseases

Area of Science:

• Hepatology
• Nanotechnology
• Microbiome research

Background:

• Chronic liver diseases (CLDs), including alcohol-associated and metabolic dysfunction-associated steatotic liver diseases, stem from metabolic and immune dysregulation, alongside gut microbiome changes.
• Current CLD treatments offer limited efficacy, highlighting the need for novel therapeutic strategies targeting the gut-liver axis.

Purpose of the Study:

• To review the role of nanocarriers in modulating the gut microbiome for CLD therapy.
• To explore the integration of nanotechnology, microbiome therapeutics, and artificial intelligence (AI) for personalized CLD treatment.

Main Methods:

• Overview of CLDs, nanocarrier types, and their application in microbiome modulation for liver disease.
• Discussion of AI's role in accelerating nanoparticle design and optimizing microbial therapies.
• Exploration of challenges and future directions for gut microbiome-focused nano-drug delivery.

Main Results:

• Nanoparticles offer targeted delivery and stability for microbiome-based therapies.
• AI can optimize nanoparticle design, microbial formulations, and predict treatment responses.
• Integration of these technologies shows potential for personalized CLD interventions.

Conclusions:

• Nanotechnology and AI-driven precision medicine hold significant promise for advancing CLD treatment.
• Targeting gut-liver communication via microbiome modulation with nanocarriers is a key area for future therapeutic development.